Article Sidebar
Views PDF: 107
The treatment results of differentiated thyroid carcinoma post-thyroidectomy with 131I at Thai Nguyen oncology centre
Main Article Content
Abstract
SUMMARY
Objectives: 1.To evaluate treatment results of differentiated thyroid carcinoma patients post-thyroidectomy with 131I. 2. To study some factors related to treatment results.
Materials and method: A descriptive study was conducted on 87 diffentiated thyroid carcinoma patients treated at Thai Nguyen oncology centre
from 2011 to 2018.
Results: Medial age of patients was 47.3 ± 12.7, female : male = 4.8 : 1. 67 % were papilliary thyroid carcinoma, 63.2 % had no metastases, 32.2 % had cervical nodal metastases, 4.6 % had distant metastases. 95.4 % of patients were
in stage I, II, III. Post-operative thyroid remnants were 3.52 ± 1.73 g. The rates of patients responding completely after 1, 2, 3 and over 3 doses of 131I were 60.9 %, 79.3 %, 87.4 % and 92 % respectively. Medial total treatment dose of 131I used was 112.5 ± 31.2 mCi, medial treatment times were 1.83 ± 0.3 times. In patients with no distant metastases, the thyroid remnant ablation of 131I with doses from
30 to 50 mCi was as well as with dose of 100 mCi. The treatment results in patients under 45 years were better than in patients over 45 years, in patients with no metastases and cervical nodal metastases were better than in patients with
distant metastases, in patients in stage I, II and III were better than in patients in stage IV, in patients with thyroid remnants < 2 g were better than in patients with those ≥ 2 g, in patients with serum Tg < 10 ng/dL or serum TgAb < 100 IU/mL
were better than in patients with those ≥ 10 ng/dL or ≥ 100 IU/mL respectively.
Conclusion: The treatment effectiveness of 131I with low dose (30 – 50 mCi) was equivalent to high dose of 100 mCi in patients with no distant
metastases. 60.9 % of patients had good results after only 1 dose of 131I. With medial dose of 112.5 ± 31.2 mCi of 131I, after 1.83 ± 0.3 treatment times, 92% patients was responded completely\. Patients were younger than 45 years, patients with no distant metastases, in earlier stages of cancer, with less thyroid remnants, with lower levels of serum Tg or serum TgAb responded better than to the treatment.
Article Details
Keywords
Differentiated Thyroid Carcinoma (DTC),, 131I, Thyroglobulin (Tg), Anti Thyroglobulin (TgAb), Whole Body Scan (WBS
References
1. Nguyễn Thị Lan Hương: (2013): “Đánh giá hiệu quả điều trị ung thư tuyến giáp biệt hóa sau phẫu thuật bằng 131I tại Viện Y học phóng xạ và U bướu Quân đội”. Tạp chí Ung thư học Việt Nam, số 4, trang 54- 59.
2. Mai Trọng Khoa, Phan Sỹ An, Trần Đình Hà và cộng sự (2006): “Hiệu quả của 131I trong điều trị ung thư tuyến
giáp thể biệt hóa”. Tạp chí Y học lâm sàng, số đặc san, trang 13 - 22.
3. Trần Văn Thiệp, Trần Đặng Ngọc Linh, Nguyễn Thành Công, Nguyễn Hữu Phúc (2013): “Hiệu quả diệt giáp bằng 131I liều thấp sau phẫu thuật ung thư tuyến giáp thể biệt hóa”. Tạp chí Ung thư học Việt Nam, số 4, trang 119 - 125.
4. Apichaya Claimon, Pawana Pusuwan, Benjapa Khiewvan (2017): ‘Factors influcing the success of the first radioiodine therapy for differentiated thyroid carcinoma’. Journal of the medical association of Thailand, 100(2), pp. 207 - 218.
5. Kai Guo, Zhuoying Wang (2014): ‘Risk factors influencing the recurrence papillary thyroid carcinoma: a systematic review and meta-analysic’. Int J. Clin Exp Pathol. 7(9), pp. 5393 - 5403.
6. J. D. Lin, P. F. Kao, T. C. Chao (1998): ‘The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma’. The British Journal of Radiology. 71(843), pp. 307 – 313.
7. Na Liu, Zhaowei Meng, Qiang Jia, Jian Tan et al (2016): ‘Multiple - factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status’. Scientific Report. 6, pp. 1 – 7.
8. Thamnirat K., Utamakul C., Chamroonrat W., Kositwattanarerk A., Anongpomjossakul Y.,Sritara C. (2015):
‘Factors affecting disease – free status of differentiated thyroid carcinoma patients’. Asian Pac J Cancer Prev. 16(2), pp. 737 - 740.